COMMUNIQUÉ DE PRESSE publié le 15/05/2025 à 09:00, il y a 1 année 1 mois Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer Lonza appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer, effective July 1, 2025. Previously Lonza's Group General Counsel, he brings extensive experience in legal and corporate governance. Basel, Switzerland, 15 May 2025 Switzerland Lonza Chief Legal Officer Corporate Affairs Andreas Bohrer
BRÈVE publiée le 09/05/2025 à 16:35, il y a 1 année 1 mois Lonza's 2025 AGM: All Proposals Receive Shareholder Approval Shareholder Approval Dividend Announcement Board Elections AGM 2025 Deloitte Reappointment
BRÈVE publiée le 09/05/2025 à 16:35, il y a 1 année 1 mois Assemblée générale annuelle 2025 de Lonza : toutes les propositions reçoivent l'approbation des actionnaires Approbation Des Actionnaires Élections Du Conseil D'administration Annonce De Dividendes Assemblée Générale Annuelle 2025 Renouvellement Du Mandat De Deloitte
COMMUNIQUÉ DE PRESSE publié le 09/05/2025 à 16:30, il y a 1 année 1 mois Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved Lonza Group AG announces results of 2025 Annual General Meeting, re-elects Chair & elects new Board members. Dividend of CHF 4.00 per share approved. Deloitte re-elected as auditor for 2026 Board Of Directors Dividend Lonza Group AG Deloitte 2025 Annual General Meeting
BRÈVE publiée le 09/05/2025 à 06:35, il y a 1 année 1 mois Lonza Demonstrates Strong Q1 2025 Performance Share Buyback Sales Growth Lonza Q1 2025 CDMO Performance CHI Recovery
BRÈVE publiée le 09/05/2025 à 06:35, il y a 1 année 1 mois Lonza affiche de solides performances au premier trimestre 2025 Rachat D'actions Croissance Des Ventes Lonza T1 2025 Performances CDMO Récupération Du CHI
COMMUNIQUÉ DE PRESSE publié le 09/05/2025 à 06:30, il y a 1 année 1 mois Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in Line with Expectations for Full-Year 2025 Lonza reports strong Q1 2025 performance in CDMO and CHI businesses, with outlook confirming sales growth and margin improvement for 2025 CDMO Lonza Outlook Q1 2025 CHI
BRÈVE publiée le 03/04/2025 à 07:05, il y a 1 année 2 mois Lonza Group Prepares for 2025 AGM and Releases 2024 Reports Board Of Directors Sustainability Dividend Proposal AGM 2025 2024 Reports
BRÈVE publiée le 03/04/2025 à 07:05, il y a 1 année 2 mois Le groupe Lonza se prépare pour l'assemblée générale annuelle de 2025 et publie ses rapports pour 2024 Conseil D'administration Durabilité Proposition De Dividende Assemblée Générale Annuelle 2025 Rapports 2024
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 07:00, il y a 1 année 2 mois Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports Lonza publishes invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports. Re-election and election of Board members, proposed dividend of CHF 4.00 per share maintained Dividend Lonza Sustainability Reports 2025 Annual General Meeting 2024 Annual Report
Publié le 30/06/2026 à 15:06, il y a 1 heure 25 minutes 260630 BENETEAU Transactions sur actions propres
Publié le 30/06/2026 à 07:30, il y a 9 heures 2 minutes Gimv sells its stake in AlpenBlu Clinics (formerly Les Psy Réunis), a Swiss provider of outpatient mental healthcare, to Impact Healthcare.
Publié le 30/06/2026 à 07:30, il y a 9 heures 2 minutes Gimv cède sa participation dans AlpenBlu Clinics (précédemment Les Psy Réunis), acteur suisse des soins ambulatoires en santé mentale, à Impact Healthcare
Publié le 30/06/2026 à 15:00, il y a 1 heure 32 minutes Four Nines Gold Advances Toward Maiden Drill Program with Property-Wide Geophysical Survey at Hayden Hill
Publié le 30/06/2026 à 15:00, il y a 1 heure 32 minutes BlackBerry AtHoc Strengthens Enterprise Readiness as Cyber, Climate, and Geopolitical Uncertainty Rises
Publié le 30/06/2026 à 15:00, il y a 1 heure 32 minutes Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Publié le 30/06/2026 à 14:30, il y a 2 heures 2 minutes NV Gold Announces Non-Brokered Private Placement
Publié le 30/06/2026 à 14:00, il y a 2 heures 32 minutes Datametrex Announces Completion of AI-Based Evaluation of 2 Patents and Launch of Licensing Initiative
Publié le 30/06/2026 à 16:05, il y a 26 minutes Selective PPARα Modulator "K-808" (Pemafibrate) Granted "Breakthrough Therapy" Designation by the U.S. Food and Drug Administration (FDA) As a Treatment for Primary Biliary Cholangitis